ZYBERNO
Stock Report
Updated Sep 1, 2026

VERU INC. (VERU)

Healthcare • NASDAQ

$2.80

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
14.0/100
POOR BUSINESS
VERU INC. (VERU) scores 14/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-102.7%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.21x)
Operating Margin (Operational Efficiency):CRITICAL (-354.0%)
Return on Capital (Capital Efficiency):CRITICAL (-392.4%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

VERU INC. (VERU) stock report — Zyberno Score 14/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, VERU generated -$24.88M in Owner Earnings. Reinvestment rate: 58.9%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:2.80
Market Cap:$64.54M

Valuation Multiples (3)

P/B Ratio:2.27x
P/S Ratio:6.08x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$43.34M

Price Action & Momentum (3)

Momentum Percentile:10 / 100
% of 52-Week High:38.2%
B. Profitability Assessment

Return Metrics (5)

ROA:-77.3%
Reinvestment Rate:58.9%
Fundamental Growth Rate (g):-231.0%

Margin Analysis (3)

Operating Margin Ttm:-354.0%
Net Margin Ttm:-287.0%
Ebitda Margin:-352.9%

TTM Performance (3)

Gross Margin Ttm:55.2%
Operating Margin Ttm:-354.0%
Net Margin Ttm:-287.0%

Yield Metrics (2)

Earnings Yield:-$13.75
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:86.4%
Latest Earnings Filed:2024-05-08

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-38.0%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:4.42x
Quick Ratio:3.75x
Cash Ratio:3.88x

Leverage Analysis (3)

Debt To Equity Ttm:0.21x
Debt-to-Equity Ratio:0.21x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-284.04x
Times Interest Earned:-284.04

Capital Structure (4)

Working Capital:21,072,455.00
Cash And Cash Equivalents:23,880,142.00
Long Term Debt:$1.91M
Net Debt:-$21.20M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $10.61M
Linear Growth: -38.0%
📊 Click to view full VERU Revenue analysis & methodology →
Cost Of Revenue Ttm:$11.03M

Profitability Breakdown (2)

Gross profit TTM: $5.85M
Linear Growth: -50.0%
📊 Click to view full VERU Gross Profit analysis & methodology →
-$37.56M

Bottom Line Performance (3)

-$30.46M
Income Before Tax:$0.00
Ebitda Ttm:-37,448,064.00

Operating Expenses (5)

Operating Expenses:27,816,027.00
R And D Expense:11,761,323.00
Sga Expense:16,054,704.00
Income Tax Expense:$0.00
Interest Expense:127,336.00

Expense Ratios (1)

Ebitda Margin:-352.9%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$37.03M
Current Assets:$27.23M
Ppe Net:965,443.00
Goodwill:6,878,932.00
Intangible Assets:$5.95K

Liability Structure (4)

Total Liabilities:8,651,430.00
Current Liabilities:6,155,872.00
Long Term Debt:$1.91M
Short Term Debt:$775.16K

Equity & Capital (3)

Equity:$28.38M
Retained Earnings:-$332.36M
Common Stock:308,000,000.00

Working Capital Items (3)

Accounts Receivable:3,960,305.00
Inventory:4,144,179.00
Accounts Payable:1,709,689.00

Special Items (2)

Contract Liabilities:333,000.00
Stock Based Compensation:577,969.00
C. Cash Flow Analysis

Operating Activities (2)

-$24.88M-$24.88M

Investment Activities (2)

Investing Cash Flow:$0.00
Capital Expenditures Ttm:0.00

Financing Activities (3)

Financing Cash Flow:$23.37M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:112,766.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.62
-$0.37
Earnings Per Share Ttm:-$1.32

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.46
Operating Cash Flow Per Share:-$0.94

Book Value & Capital (2)

Book Value Per Share:$1.23
Cash Per Share:1.04

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.27x
Working Capital Turnover Ttm:0.50x

Receivables Management (2)

Receivables Turnover Ttm:2.68x
Days Sales Outstanding Ttm:136.24

Inventory Management (2)

Inventory Turnover Ttm:2.66x
Days Inventory Outstanding Ttm:137.11

Payables & Cash Cycle (2)

Days Payable Outstanding:56.56
Cash Conversion Cycle:216.78
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$24.88M

Damodaran Growth Analysis (2)

Reinvestment Rate:58.9%
Fundamental Growth Rate (g):-231.0%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-38.0%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):-50.0%
Book Value Growth Rate (Linear):-25.2%
C. Company Profile & Context

Corporate Information (6)

Symbol:VERU
Company Name:VERU INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:23.05M
Shares Outstanding Basic:23.05M
Shares Outstanding Diluted:146.38M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 02:43:18 UTC
Data Timestamp:2026-08-20T09:56:26.274702
Scroll to Top